An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Open-label, single-dose (BIA 2-093 800 mg tablet), single-centre study in five groups of
subjects with various degrees of renal function based on creatinine clearance